Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Gene Silencing/Gene Editing » Data Point to Regulus Alport Drug Use in Late-stage Disease, Other Kidney Diseases

Data Point to Regulus Alport Drug Use in Late-stage Disease, Other Kidney Diseases

Nov 24, 2014
|
staff reporter
Premium

NEW YORK (GenomeWeb) ― Researchers from Sanofi recently reported preclinical data showing that Regulus Therapeutics' microRNA-21 inhibitor RG-012 can have a therapeutic benefit even in the late stages of Alport syndrome and that it can enhance the effect of the kidney protectant ramipril.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

German Shepherd's Own Sequence

A German shepherd called Nala has had her genome sequenced.

And Now Serology Tests

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Young at Brain

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

Science Paper Examines Factors to Identify Metastatic Prostate Cancer Responsive to Checkpoint Inhibitors

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.

What's Popular?

In Gene Silencing/Gene Editing

  1. ERS Genomics Licenses CRISPR-Cas9 Patents to Axxam

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.